Brief: Kamada Announces Enrollment Of First Patient In Phase 1/2 Clinical Trial For Covid-19

Kamada

10/08/2020 12:45

Aug 10 (Reuters) - Kamada Ltd  KMDA.TA :
    * KAMADA ANNOUNCES ENROLLMENT OF FIRST PATIENT IN ITS PHASE
1/2
CLINICAL TRIAL OF ITS PLASMA-DERIVED IMMUNOGLOBULIN (IGG)
PRODUCT AS A POTENTIAL TREATMENT FOR CORONAVIRUS DISEASE
(COVID-19) IN ISRAEL
    * KAMADA LTD - PRE-IND MEETING FOR IGG PRODUCT WITH FDA TO
BE
CONDUCTED IN CURRENT QUARTER, WITH U.S. CLINICAL DEVELOPMENT
EXPECTED TO START IN EARLY 2021
    * KAMADA LTD - INTENDS TO FURTHER EXPLORE POTENTIAL OF ITS
IGG
PRODUCT TO PREVENT COVID-19 DISEASE IN HEALTHY SUBJECTS AT RISK
IN A SEPARATE STUDY

Source text for Eikon:  ID:nGNX9jD5NX 
Further company coverage:  KMDA.TA 

 ((Reuters.Briefs@thomsonreuters.com;))